Exploring a Cost-Efficient Model for Predicting Cerebral Aβ Burden Using MRI and Neuropsychological Markers in the ADNI-2 Cohort
- PMID: 33121011
- PMCID: PMC7712671
- DOI: 10.3390/jpm10040197
Exploring a Cost-Efficient Model for Predicting Cerebral Aβ Burden Using MRI and Neuropsychological Markers in the ADNI-2 Cohort
Abstract
Many studies have focused on the early detection of Alzheimer's disease (AD). Cerebral amyloid beta (Aβ) is a hallmark of AD and can be observed in vivo via positron emission tomography imaging using an amyloid tracer or cerebrospinal fluid assessment. However, these methods are expensive. The current study aimed to identify and compare the ability of magnetic resonance imaging (MRI) markers and neuropsychological markers to predict cerebral Aβ status in an AD cohort using machine learning (ML) approaches. The prediction ability of candidate markers for cerebral Aβ status was examined by analyzing 724 participants from the ADNI-2 cohort. Demographic variables, structural MRI markers, and neuropsychological test scores were used as input in several ML algorithms to predict cerebral Aβ positivity. Out of five combinations of candidate markers, neuropsychological markers with demographics showed the most cost-efficient result. The selected model could distinguish abnormal levels of Aβ with a prediction ability of 0.85, which is the same as that for MRI-based models. In this study, we identified the prediction ability of MRI markers using ML approaches and showed that the neuropsychological model with demographics can predict Aβ positivity, suggesting a more cost-efficient method for detecting cerebral Aβ status compared to MRI markers.
Keywords: Alzheimer’s disease; amyloid beta; machine learning; neuropsychological assessment.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Cognitive Profiling Related to Cerebral Amyloid Beta Burden Using Machine Learning Approaches.Front Aging Neurosci. 2019 Apr 26;11:95. doi: 10.3389/fnagi.2019.00095. eCollection 2019. Front Aging Neurosci. 2019. PMID: 31105554 Free PMC article.
-
The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.Eur J Neurol. 2019 May;26(5):733-e53. doi: 10.1111/ene.13881. Epub 2019 Jan 20. Eur J Neurol. 2019. PMID: 30561868
-
Detecting Amyloid Positivity in Elderly With Increased Risk of Cognitive Decline.Front Aging Neurosci. 2020 Jul 30;12:228. doi: 10.3389/fnagi.2020.00228. eCollection 2020. Front Aging Neurosci. 2020. PMID: 32848707 Free PMC article.
-
Spreading of amyloid, tau, and microvascular pathology in Alzheimer's disease: findings from neuropathological and neuroimaging studies.J Alzheimers Dis. 2014;42 Suppl 4:S421-9. doi: 10.3233/JAD-141461. J Alzheimers Dis. 2014. PMID: 25227313 Review.
-
Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.Prog Neurobiol. 2013 Sep;108:21-43. doi: 10.1016/j.pneurobio.2013.06.004. Epub 2013 Jul 11. Prog Neurobiol. 2013. PMID: 23850509 Review.
References
-
- World Health Organization . Dementia: A Public Health Priority. World Health Organization; Geneva, Switzerland: 2012.
LinkOut - more resources
Full Text Sources